1. van der Meer, AJ, Wedemeyer, H, Feld, JJ, et al. Is there sufficient evidence to recommend antiviral therapy in hepatitis C? J Hepatol 2014; 60: 191–196.
Google Scholar | Crossref | Medline2. Colombo, M, Boccaccio, V. HCV therapy and risk of liver cancer recurrence: who to treat? Nat Rev Gastroenterol Hepatol 2018; 15: 392–393.
Google Scholar | Crossref | Medline3. Ioannou, GN, Green, PK, Berry, K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol 2017; 68: 25–32.
Google Scholar4. Kanwal, F, Kramer, J, Asch, SM, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 2017; 153: 996–1005.e1.
Google Scholar | Crossref | Medline5. Ogawa, E, Furusyo, N, Nomura, H, et al. Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment. Aliment Pharmacol Ther 2018; 47: 104–113.
Google Scholar | Crossref | Medline6. Mettke, F, Schlevogt, B, Deterding, K, et al. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. Aliment Pharmacol Ther 2018; 47: 516–525.
Google Scholar | Crossref | Medline7. Reig, M, Marino, Z, Perello, C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016; 65: 719–726.
Google Scholar | Crossref | Medline8. Debes, JD, van Tilborg, M, Groothuismink, ZMA, et al. Levels of cytokines in serum associate with development of hepatocellular carcinoma in patients with HCV infection treated with direct-acting antivirals. Gastroenterology 2017; 154: 515–517.E3.
Google Scholar | Crossref | Medline9. Villani, R, Facciorusso, A, Bellanti, F, et al. DAAs rapidly reduce inflammation but increase serum VEGF level: A rationale for tumor risk during anti-HCV treatment. PLoS One 2016; 11: e0167934.
Google Scholar | Crossref | Medline10. Capone, F, Costantini, S, Guerriero, E, et al. Serum cytokine levels in patients with hepatocellular carcinoma. Eur Cytokine Netw 2010; 21: 99–104.
Google Scholar | Medline11. Owusu Sekyere, S, Schlevogt, B, Mettke, F, et al. HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection. Liver Cancer 2019; 8: 41–65.
Google Scholar | Crossref | Medline12. Assarsson, E, Lundberg, M, Holmquist, G, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One 2014; 9: e95192.
Google Scholar | Crossref | Medline | ISI13. Lundberg, M, Eriksson, A, Tran, B, et al. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res 2011; 39: e102.
Google Scholar | Crossref | Medline | ISI14. Thorsen, SB, Lundberg, M, Villablanca, A, et al. Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomatic individuals. J Transl Med 2013; 11: 253-5876–11-253.
Google Scholar | Crossref | Medline15. Debes, JD, de Knegt, RJ, Boonstra, A. The path to cancer and back: immune modulation during hepatitis C virus infection, progression to fibrosis and cancer, and unexpected roles of new antivirals. Transplantation 2017; 101: 910–915.
Google Scholar | Crossref | Medline16. Couper, KN, Blount, DG, Riley, EM. IL-10: The master regulator of immunity to infection. J Immunol 2008; 180: 5771–5777.
Google Scholar | Crossref | Medline | ISI17. de Souza-Cruz, S, Victória, MB, Tarragô, AM, et al. Liver and blood cytokine microenvironment in HCV patients is associated to liver fibrosis score: a proinflammatory cytokine ensemble orchestrated by TNF and tuned by IL-10. BMC Microbiol 2016; 16: 3-015-0610-6.
Google Scholar | Crossref | Medline18. Smith, LK, Boukhaled, GM, Condotta, SA, et al. Interleukin-10 directly inhibits CD8(+) T cell function by enhancing N-glycan branching to decrease antigen sensitivity. Immunity 2018; 48: 299–312.e5.
Google Scholar | Crossref | Medline19. Carlin, AF, Aristizabal, P, Song, Q, et al. Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection. Hepatology 2015; 62: 1047–1058.
Google Scholar | Crossref | Medline20. Saraiva, GN, do Rosario, NF, Medeiros, T, et al. Restoring inflammatory mediator balance after sofosbuvir-induced viral clearance in patients with chronic hepatitis C. Mediators Inflamm 2018; 2018: 8578051.
Google Scholar | Crossref | Medline21. Fouquet, G, Marcq, I, Debuysscher, V, et al. Signaling lymphocytic activation molecules Slam and cancers: Friends or foes?. Oncotarget 2018; 9: 16248–16262.
Google Scholar | Crossref | Medline22. van Driel, BJ, Liao, G, Engel, P, et al. Responses to microbial challenges by SLAMF receptors. Front Immunol 2016; 7: 4.
Google Scholar | Crossref | Medline | ISI23. Wu, N, Veillette, A. SLAM family receptors in normal immunity and immune pathologies. Curr Opin Immunol 2016; 38: 45–51.
Google Scholar | Crossref | Medline24. Dragovich, MA, Mor, A. The SLAM family receptors: Potential therapeutic targets for inflammatory and autoimmune diseases. Autoimmun Rev 2018; 17: 674–682.
Google Scholar | Crossref | Medline25. Mehrle, S, Schmidt, J, Büchler, MW, et al. Enhancement of anti-tumor activity in vitro and in vivo by CD150 and SAP. Mol Immunol 2008; 45: 796–804.
Google Scholar | Crossref | Medline26. Hengst, J, Falk, CS, Schlaphoff, V, et al. Direct-acting antiviral-induced hepatitis C virus clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C. J Infect Dis 2016; 214: 1965–1974.
Google Scholar | Crossref | Medline